摘要
目的探讨新的抗肿瘤药物剂型-多西他赛微球体(D-MS)在消化道恶性肿瘤所致腹膜转移癌中的治疗效果。方法将220只BDF1小鼠分为11组,用B-16 Melanoma溶液注射后,经过4天形成腹膜转移癌,分别注入不同剂型及剂量的多西他赛,使用小样本计数的χ2检验,分析各组小鼠的平均生存期。结果在D-MS组,随着多西他赛含量的增加,生存期也随之增加。在100 mg/kg组,平均生存期为28.9天,在400 mg/kg组,平均生存期达到114天。而在多西他赛水溶液组,随着多西他赛含量的增加,平均生存期并未随之增加,在多西他赛含量100 mg/kg组,平均生存期为28天,而在200 mg/kg组,平均生存期也仅为29天。结论 D-MS可以作为新的抗肿瘤剂型用于腹膜转移癌的治疗中。
Objective To investigate the therapeutic effects of Docetaxel microspheres(D-MS), a new antitumor drug dosage form, on peritoneal metastatic carcinoma. Methods Two hundred and twenty BDF1 mice were divided into 11 groups, receiving intraperitoneal inoculation with B-16 PC melanoma for 4 days, until peritoneal metastatic carcinoma was formed. Docetaxel was administered with different formulations and doses. Average survival time was analyzed by chi-square test. Results D-MS extended the survival of mice with increasing dose of docetaxel. The average survival time of 100 and 400 mg/kg group were 28.9 and 114 days. While no significant effect was on aqueous solution of docetaxel group, as the average survival time of 100 and 200 mg/kg group were 28 and 29 days. Conclusion D-MS could be used as a new antitumor drug dosage form in the treatment of peritoneal metastatic carcinoma.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2014年第7期711-713,共3页
Cancer Research on Prevention and Treatment
关键词
多西他赛微球体
腹膜转移癌
治疗作用
Docetaxel microspheres(D-MS)
Peritoneal carcinomatosis(PC)
Therapeutic effects
